August 24, 2017 / 12:14 PM / in 3 months

BRIEF-Boehringer Ingelheim initiates phase IIA study of compound acquired from Pharmaxis

Aug 24 (Reuters) - Pharmaxis Ltd

* Boehringer Ingelheim initiates phase IIA study of compound acquired from Pharmaxis in debilitating liver disease nash Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below